{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T03:39:13Z","timestamp":1795145953742,"version":"4.10.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1038\/s41591-023-02392-7","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T16:02:18Z","timestamp":1685721738000},"page":"1728-1737","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4470-8425","authenticated-orcid":false,"given":"Priscilla K.","family":"Brastianos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert E.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2496-7737","authenticated-orcid":false,"given":"Anita","family":"Giobbie-Hurder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eudocia Q.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy U.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4438-7000","authenticated-orcid":false,"given":"Beth","family":"Overmoyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Y.","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine V.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorg","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Eichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca S.","family":"Heist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Krop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Ligibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5940-8671","authenticated-orcid":false,"given":"Sara","family":"Tolaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5430-8957","authenticated-orcid":false,"given":"Erica","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Winer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Bent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali A.","family":"de Sauvage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazanin","family":"Ijad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana M.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Braxton","family":"Marion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Nason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naina","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Ratcliff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Summers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Mahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen A.","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Cahill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R.","family":"Gerstner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5344-6645","authenticated-orcid":false,"given":"Ryan J.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,2]]},"reference":[{"key":"2392_CR1","doi-asserted-by":"publisher","first-page":"310","DOI":"10.6004\/jnccn.2018.0012","volume":"16","author":"WJ Gradishar","year":"2018","unstructured":"Gradishar, W. J. et al. Clinical practice guidelines in oncology. J. Natl Compr. Cancer Netw. 16, 310\u2013320 (2018).","journal-title":"J. Natl Compr. Cancer Netw."},{"key":"2392_CR2","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1158\/2159-8290.CD-15-0369","volume":"5","author":"PK Brastianos","year":"2015","unstructured":"Brastianos, P. K. et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov. 5, 1164\u20131177 (2015).","journal-title":"Cancer Discov."},{"key":"2392_CR3","doi-asserted-by":"publisher","first-page":"5537","DOI":"10.1158\/1078-0432.CCR-13-3003","volume":"20","author":"G Chen","year":"2014","unstructured":"Chen, G. et al. Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. Clin. Cancer Res. 20, 5537\u20135546 (2014).","journal-title":"Clin. Cancer Res."},{"key":"2392_CR4","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1158\/2159-8290.CD-18-1489","volume":"9","author":"GM Fischer","year":"2019","unstructured":"Fischer, G. M. et al. Molecular profiling reveals unique immune and metabolic features of melanoma brain metastases. Cancer Discov. 9, 628\u2013645 (2019).","journal-title":"Cancer Discov."},{"key":"2392_CR5","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1038\/s41467-020-16164-1","volume":"11","author":"N Kim","year":"2020","unstructured":"Kim, N. et al. Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. Nat. Commun. 11, 2285 (2020).","journal-title":"Nat. Commun."},{"key":"2392_CR6","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1805453","volume":"379","author":"HA Tawbi","year":"2018","unstructured":"Tawbi, H. A. et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N. Engl. J. Med. 379, 722\u2013730 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2392_CR7","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","volume":"21","author":"SB Goldberg","year":"2020","unstructured":"Goldberg, S. B. et al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol. 21, 655\u2013663 (2020).","journal-title":"Lancet Oncol."},{"key":"2392_CR8","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/S1470-2045(21)00545-3","volume":"22","author":"HA Tawbi","year":"2021","unstructured":"Tawbi, H. A. et al. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncol. 22, 1692\u20131704 (2021).","journal-title":"Lancet Oncol."},{"key":"2392_CR9","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","volume":"19","author":"GV Long","year":"2018","unstructured":"Long, G. V. et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 19, 672\u2013681 (2018).","journal-title":"Lancet Oncol."},{"key":"2392_CR10","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3816\/CCC.2005.n.022","volume":"5","author":"ML Sundermeyer","year":"2005","unstructured":"Sundermeyer, M. L., Meropol, N. J., Rogatko, A., Wang, H. & Cohen, S. J. Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin. Colorectal Cancer 5, 108\u2013113 (2005).","journal-title":"Clin. Colorectal Cancer"},{"key":"2392_CR11","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","volume":"21","author":"T Powles","year":"2020","unstructured":"Powles, T. et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 21, 1563\u20131573 (2020).","journal-title":"Lancet Oncol."},{"key":"2392_CR12","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1038\/s41467-022-29052-7","volume":"13","author":"PK Brastianos","year":"2022","unstructured":"Brastianos, P. K. et al. Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas. Nat. Commun. 13, 1325 (2022).","journal-title":"Nat. Commun."},{"key":"2392_CR13","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/s41591-020-0918-0","volume":"26","author":"PK Brastianos","year":"2020","unstructured":"Brastianos, P. K. et al. Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat. Med. 26, 1280\u20131284 (2020).","journal-title":"Nat. Med."},{"key":"2392_CR14","doi-asserted-by":"publisher","unstructured":"Lin, N. U. et al. Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol. https:\/\/doi.org\/10.1016\/S1470-2045(15)70057-4 (2015).","DOI":"10.1016\/S1470-2045(15)70057-4"},{"key":"2392_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026 (2009).","journal-title":"Eur. J. Cancer"},{"key":"2392_CR16","doi-asserted-by":"publisher","first-page":"E1540","DOI":"10.1073\/pnas.1714089115","volume":"115","author":"D Taggart","year":"2018","unstructured":"Taggart, D. et al. Anti\u2013PD-1\/anti\u2013CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+T cell trafficking. Proc. Natl Acad. Sci. USA 115, E1540\u2013E1549 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2392_CR17","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s00262-008-0467-8","volume":"57","author":"DL Thomas","year":"2008","unstructured":"Thomas, D. L., Kranz, D. M. & Roy, E. J. Experimental manipulations of afferent immune responses influence efferent immune responses to brain tumors. Cancer Immunol. Immunother. 57, 1323\u20131333 (2008).","journal-title":"Cancer Immunol. Immunother."},{"key":"2392_CR18","doi-asserted-by":"publisher","first-page":"6451","DOI":"10.1158\/0008-5472.CAN-06-3280","volume":"67","author":"K Sasaki","year":"2007","unstructured":"Sasaki, K. et al. Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors. Cancer Res. 67, 6451\u20136458 (2007).","journal-title":"Cancer Res."},{"key":"2392_CR19","doi-asserted-by":"publisher","first-page":"845","DOI":"10.4049\/jimmunol.179.2.845","volume":"179","author":"F Masson","year":"2007","unstructured":"Masson, F. et al. Brain microenvironment promotes the final functional maturation of tumor-specific effector CD8+T cells. J. Immunol. 179, 845\u2013853 (2007).","journal-title":"J. Immunol."},{"key":"2392_CR20","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s43018-021-00198-5","volume":"2","author":"PK Brastianos","year":"2021","unstructured":"Brastianos, P. K. et al. Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations. Nat. Cancer 2, 498\u2013502 (2021).","journal-title":"Nat. Cancer"},{"key":"2392_CR21","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.6004\/jnccn.2013.0133","volume":"11","author":"PK Brastianos","year":"2013","unstructured":"Brastianos, P. K., Curry, W. T. & Oh, K. S. Clinical discussion and review of the management of brain metastases. JNCCN J. Natl Compr. Canc. Netw. 11, 1153\u20131164 (2013).","journal-title":"JNCCN J. Natl Compr. Canc. Netw."},{"key":"2392_CR22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0527","author":"PW Sperduto","year":"2012","unstructured":"Sperduto, P. W. et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2011.38.0527 (2012).","journal-title":"J. Clin. Oncol."},{"key":"2392_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.06.074","author":"PW Sperduto","year":"2008","unstructured":"Sperduto, P. W., Berkey, B., Gaspar, L. E., Mehta, M. & Curran, W. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int. J. Radiat. Oncol. Biol. Phys. https:\/\/doi.org\/10.1016\/j.ijrobp.2007.06.074 (2008).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"2392_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(96)00619-0","author":"L Gaspar","year":"1997","unstructured":"Gaspar, L. et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int. J. Radiat. Oncol. Biol. Phys. https:\/\/doi.org\/10.1016\/S0360-3016(96)00619-0 (1997).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"2392_CR25","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber, J. et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N. Engl. J. Med. 377, 1824\u20131835 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2392_CR26","doi-asserted-by":"publisher","DOI":"10.1001\/JAMAONCOL.2023.0147","author":"KJ Harrington","year":"2023","unstructured":"Harrington, K. J. et al. Efficacy and safety of nivolumab plus ipilimumab vs nivolumab alone for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck: the phase 2 CheckMate 714 randomized clinical trial. JAMA Oncol. https:\/\/doi.org\/10.1001\/JAMAONCOL.2023.0147 (2023).","journal-title":"JAMA Oncol."},{"key":"2392_CR27","doi-asserted-by":"publisher","unstructured":"Wakelee, H. A. et al. IMpower010: primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (NSCLC). J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.8500 (2021).","DOI":"10.1200\/JCO.2021.39.15_suppl.8500"},{"key":"2392_CR28","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","volume":"17","author":"SB Goldberg","year":"2016","unstructured":"Goldberg, S. B. et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 17, 976\u2013983 (2016).","journal-title":"Lancet Oncol."},{"key":"2392_CR29","unstructured":"US Food and Drug Administration. Cancer clinical trial eligibility criteria: brain metastases. Guidance for industry. https:\/\/www.fda.gov\/media\/121317\/download (2020)."},{"key":"2392_CR30","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1200\/JCO.18.01511","volume":"37","author":"RA Freedman","year":"2019","unstructured":"Freedman, R. A. et al. TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J. Clin. Oncol. 37, 1081\u20131089 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2392_CR31","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","volume":"13","author":"K Margolin","year":"2012","unstructured":"Margolin, K. et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 13, 459\u2013465 (2012).","journal-title":"Lancet Oncol."},{"key":"2392_CR32","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1200\/JCO.2007.12.3588","volume":"26","author":"NU Lin","year":"2008","unstructured":"Lin, N. U. et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 26, 1993\u20131999 (2008).","journal-title":"J. Clin. Oncol."},{"key":"2392_CR33","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1158\/1078-0432.CCR-08-1080","volume":"15","author":"NU Lin","year":"2009","unstructured":"Lin, N. U. et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin. Cancer Res. 15, 1452\u20131459 (2009).","journal-title":"Clin. Cancer Res."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02392-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02392-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02392-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T13:10:29Z","timestamp":1689685829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02392-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,2]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["2392"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02392-7","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,2]]},"assertion":[{"value":"8 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.K.B. consulted for Tesaro, Angiochem, Genentech-Roche, ElevateBio, Eli Lilly, SK Life Sciences, Pfizer, Voyager Therapeutics, Sintetica, MPM, Advise Connect Inspire, Kazia and Dantari, received institutional research funding (to MGH) from Merck, Mirati, Eli Lilly, Kinnate, BMS and Pfizer and has received honoraria from Merck, Medscape, Pfizer, and Genentech-Roche. B.O. has received clinical trial support from Incyte and Eisai. J.D. has served as a consultant for Amgen, Blue Earth Diagnostics and Unum Therapeutics and received research support (to MGH) from Novartis and Eli Lilly. R.S.H. consulted for AbbVie, Daichii Sankyo, EMD Serono, Lilly, Novartis, Regeneron, and Sanofi; and received institutional research funding (to MGH) from Abbvie, Agios, Corvus, Daichii Sankyo, Erasca, Exelixis, Lilly, Mirati, Novartis and Turning Point. P.Y.W. received institutional research funding (to DF\/HCC) from AstraZeneca\/Medimmune, Beigene, Celgene, Chimerix, Eli Lilly, Erasca, Genentech\/Roche, Kazia, MediciNova, Merck, Novartis, Nuvation Bio, Puma, Servier, Vascular Biogenics and VBI Vaccines, and has served on the scientific advisory board for AstraZeneca, Bayer, Black Diamond, Celularity, Chimerix, Day One Bio, Genenta, Mundipharma, Novartis, Novocure, Nuvation Bio, Prelude Therapeutics, Sapience, Servier, Sagimet, Vascular Biogenics and VBI Vaccines. H.A.S. has served on the scientific advisory board for Advanced Accelerator Applications, and received institutional research funding (to MGH) from AbbVie. R.J.S. consulted for Novartis, BMS and Pfizer, and received institutional research funding (to MGH) from Merck. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}